论文部分内容阅读
目的研究病毒唑、特布他林和地塞米松雾化吸入治疗对急性喉-气管-支气管炎的临床疗效。方法将经过确诊为急性喉-气管-支气管炎的病患随机分成两组,每组共70例病患。记为对照组和联合用药组。两组患者都静脉滴注“地塞米松”。此外联合用药组在此基础上给予病毒唑和特布他林以及地塞米松的雾化吸入。结果治疗三日后,联合用药组和对照组的治愈率分别为90%和71.4%;联合用药组的各种临床症状消失时间对比于对照组显著缩短。两组比较差异具有统计学意义(P<0.05)。结论联合用药组治疗急性喉-气管-支气管炎疗效好。非常值得临床推荐。
Objective To study the clinical efficacy of ribavirin, terbutaline and dexamethasone nebulized inhalation on acute larynx-bronchitis. Methods Patients diagnosed with acute laryngotracheo-bronchitis were randomized into two groups of 70 patients each. Recorded as control group and combination group. Both groups were given “dexamethasone” intravenously. In addition, the combination group was given nebulization of ribavirin and terbutaline and dexamethasone on this basis. Results After 3 days of treatment, the cure rates of the combination group and the control group were 90% and 71.4% respectively; the disappearance time of various clinical symptoms in the combination group was significantly shortened compared with the control group. The difference between the two groups was statistically significant (P <0.05). Conclusion The combination therapy group is effective in treating acute larynx-bronchitis. Very worthy of clinical recommendation.